Inhaled corticosteroid combined with long-acting bronchodilator versus long-acting bronchodilator alone for older patients with COPD Source: International Congress 2015 – Advances in pneumonia management, COPD therapy and lung nodule evaluation Year: 2015
Emerging inhaled bronchodilators: an update Source: Eur Respir J 2009; 34: 757 Year: 2009
Pharmacokinetics of PF-00610355, a novel inhaled long-acting β2 -adrenoreceptor agonist Source: Annual Congress 2009 - Next generation bronchodilators Year: 2009
Protective effect of inhaled glucocorticosteroid and long-acting beta2-agonist combination on COPD model Source: Virtual Congress 2021 – Developments in biomarkers and treatment strategies for chronic lung diseases Year: 2021
Impact of the combination therapy: inhaled corticosteroid and long-acting beta agonists in the prescription pattern of inhaled corticosteroids Source: Annual Congress 2007 - Respiratory issues in primary care Year: 2007
Cessation of long-acting beta2-agonist in children with persistent asthma on inhaled corticosteroids Source: Eur Respir J 2016; 48: 558-560 Year: 2016
lnhaled long-acting beta-agonists as an inhaled corticosteroid-sparing agent for chronic asthma in adults Source: Eur Respir J 2005; 26: Suppl. 49, 124s Year: 2005
Efficacy and safety of Long-acting Beta-agonists+Long-acting muscarinic antagonists vs Long-acting Beta-agonists+Inhaled corticosteroids in COPD: a meta-analysis Source: International Congress 2017 – Primary care diagnosis, assessment and management of COPD Year: 2017
Triple combination of montelukast or tiotropium and inhaled corticosteroids plus long-acting ß2-agonist in persistent asthma Source: International Congress 2018 – Understanding the immunopathology that underlies airway obstructive diseases Year: 2018
Can long-acting β2 agonists substitute inhaled corticosteroids in stable persistent asthma Source: Annual Congress 2008 - Improving asthma and anti-allergic therapy Year: 2008
Efficacy of nebulized arformoterol, a long-acting β2 -adrenergic bronchodilator, in patients with COPD Source: Eur Respir J 2006; 28: Suppl. 50, 215s Year: 2006
Comparison of add-on of leukotriene receptor antagonist vs. long-acting beta2-agonist on FeNO in asthmatic children on regular inhaled budesonide Source: Eur Respir J 2002; 20: Suppl. 38, 431s Year: 2002
The effect of inhaled corticosteroids in combination with long-acting beta2-agonists in elite athletes with asthma Source: Annual Congress 2009 - Asthma and comorbid conditions Year: 2009
Concomitant use of low-dose inhaled corticosteroids and a long-acting bronchodilatator visavi doubling the dose of inhaled corticosterod in asthma patients Source: Eur Respir J 2001; 18: Suppl. 33, 98s Year: 2001
Short-acting bronchodilator and oral steroid use in asthma patients prescribed either concurrent beclometasone and salmeterol or combined salmeterol/fluticasone Source: Eur Respir J 2004; 24: Suppl. 48, 309s Year: 2004
New bronchodilators and inhaled steroids Source: Annual Congress 2011 - PG5 Asthma versus COPD: similarities and differences Year: 2011
Long-acting bronchodilators in COPD: where are we now and where are we going? Source: Breathe 2014; 10:110-120 Year: 2014
Targeting neuropetides: from antiemetics to bronchodilators? Source: Annual Congress 2012 - ERS Romain Pauwels Research Award Ceremony (supported by GlaxoSmithKline) followed by the Hot Topic "The nerves are back!" Year: 2012
Concomitant use of long-acting beta-agonists with inhaled corticosteroids among asthma patients in the UK primary care Source: Annual Congress 2007 - Miscellaneous epidemiological aspects of respiratory disease Year: 2007
Low dose inhaled corticosteroids (ICS) and short-acting beta-agonists (SABA) or long-acting beta-agonists (LABA) need in children and adolescents with asthma steps 1 and 2: what is the evidence? Source: Virtual Congress 2020 – Which paediatric asthma guidelines are the most appropriate for children and adolescents? Year: 2020